RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Other EventsItem 8.01Other Events.
On January 3, 2018, Rasna Therapeutics, Inc. issued a press release announcing follow up Phase II clinical data showing that 4 out of 9 (44%) evaluable AML patients carrying the NPM1 gene mutation treated with actinomycin D (“Act D”), achieved complete remission (CR).
The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
Rasna Therapeutics Inc. ExhibitEX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit Rasna Therapeutics,…To view the full exhibit click here
About RASNA THERAPEUTICS, INC. (OTCMKTS:RASP)
Rasna Therapeutics, Inc., formerly Active With Me Inc., creates online resources that offer travelers information on activity-based travel. The Company’s Website focuses on offering third-party content and information to visitors in their activity of choice. The Company’s Website also focuses on offering links to clubs and organizations. The Company is in development-stage. Rasna DE is the subsidiary of the Company. Rasna DE is engaged in modulating the molecular targets nucleophosmin gene (NPM1) and lysine (K)-specific demethylase 1A (LSD1), which are implicated in the disease progression of leukemia and lymphoma. The Company focuses on performing preclinical research on NPM1 and LSD1. As of June 30, 2016, the Company had not generated any revenues.
